Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma
The study confirmed the efficacy and safety of omalizumab, with its benefits persisting one year after treatment discontinuation in terms of lung function, reduction in exacerbations, decreased need for oral corticosteroids, and improved quality of life. Further research is necessary.
Authors
- Francesca Galletta (ORCID: https://orcid.org/0000-0002-4166-2030)
- Simone Foti Randazzese
- Cecilia Lugarà
- Lucia Caminiti (ORCID: https://orcid.org/0000-0003-3054-5338)
- Giuseppe Crisafulli (ORCID: https://orcid.org/0000-0001-5602-8668)
- Paolo Ruggeri (ORCID: https://orcid.org/0000-0003-0379-9869)
- Sara Manti (ORCID: https://orcid.org/0000-0002-7664-3083)
- Sebastiano Gangemi (ORCID: https://orcid.org/0000-0001-7001-6532)
- Giovanni Pioggia (ORCID: https://orcid.org/0000-0002-8089-7449)
Institutions
- University of Messina (IT)
- Istituto Ortopedico Gaetano Pini (IT)
- Institute for Biomedical Research and Innovation (IT)
- National Research Council (IT)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2025-03-07
- DOI
- https://doi.org/10.3389/falgy.2025.1529624
- Citations
- 4
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.66